Key result
Rosuvastatin cuts LDL-C by up to ~65%, outperforming atorvastatin in Phase III trials.
Why the study?
Rosuvastatin's efficacy and tolerability compared to atorvastatin for treating dyslipidaemia required comprehensive evaluation.
Does rosuvastatin improve lipid profiles compared to atorvastatin in patients with dyslipidaemia?
Does rosuvastatin improve lipid profiles compared to atorvastatin in patients with dyslipidaemia?
Rosuvastatin is a highly efficacious statin that provides significant LDL-C reduction and HDL-C elevation, allowing most patients to reach ATP III goals with a 10 mg starting dose.
No takes yet. Share an insight, caveat, or question.
May support rosuvastatin preference for LDL-C goals in dyslipidaemia; extends comparative lipid data but leaves outcome trials open.
Michael H. Davidson (2002) conducted a review in dyslipidaemia. Rosuvastatin vs. atorvastatin was evaluated on low-density lipoprotein cholesterol (LDL-C) reduction. Rosuvastatin at doses of 1-80 mg lowered LDL-C by 34-65% and demonstrated greater reductions in LDL-C compared to atorvastatin in Phase III trials.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: